home page about us location menu contacts
NeoCardium Limited is a company incorporated in United Kingdom with a focus in developing and assisting development of a new category of cardiology devices. The clinical indications for company’s proprietary device technology include applications in the practice of interventional cardiology and the new branch of Regenerative Cardiology...read more

  ORIP OneTouch

ORIP OneTouch is not just another medical device; it is a platform technology that has wide range of potential applications based on proven effects of remote ischemic pre-conditioning...                      read more

Our business is helping companies succeed in mending broken hearts. Regenerative Cardiology is all that we do for our clients, and do it as no one else does.      read more

Restenosis Prevention

Estimated 7 million angioplasties are performed worldwide annually at a cost of €5,000 to €30,000 per procedure depending upon where it’s performed. The world spends €70 billion on angioplasties & still unable to stop/prevent further worsening of the disease. Every angioplasty carries significant risk of getting restenosed within 6 months. Although Stents, now a $7 billion industry, were initially developed to prevent restenosis, in-stent restenosis still remains a serious problem resulting in either a repeat angioplasty or a bypass surgery at a substantial fiscal & health costs. NeoCardX, Company’s flagship Rx Device can potentially prevent/reduce the risk of restenosis at a tiny fraction of that cost. NeoCardX solves the problem using OMSI technology platform[1] based on alreadywell established scientific principles.[2] OMSI not only conditions the heart muscles but increases onsite expression of anti-inflammatory, anti-atherosclerotic molecules & reduces endothelial dysfunction resulting in inhibition of any new in-lesion growth.[3] Pricing at €300-€400 for 6-month treatment plan the global market for NeoCardX is highly developed yet virgin, worth well over €2 Billion, and has no other player in its class. Two NeoCardX prototype have been developed for proof-of-concept demos.

Reperfusion Injury
Revascularization surgery restores blood flow to ischemic myocardium limiting infarct size & reduces mortality, but paradoxically the reperfusion can also result in additional injury to myocardium increasing the size of the infarct. Reperfusion injury prevention is a major unmet need of interventional cardiology industry that Company’s ORIP (Optimal Remote Ischemic Preconditioning) Device addresses by utilizing already proven approach.

Regenerative Cardiology
Growing natural bypass to circumvent blocked arteries or regenerating the damaged myocardium is a new paradigm shift that has given birth to a brand new industry. Company’s path breaking AngioBoost device is positioned to address the need of firms trying to grow natural arteries & myocardium to bypass blocked coronary arteries & repair infarcted (damaged) heart. AngioBoost enables all categories of CAD patients to grow natural bypass around a clogged artery non-invasively.  AngioBoost can be a boon to over 80 heart repair firms that have invested over a billion dollars in R&D but still struggling to show efficacy with their protein/gene/stem cell based approaches.

Home | Services | Product Development | ORIP OneTouch | Partners | News | Contact Us
Copyright © NeoCardium. Designed by MriLimited - mrilimited.com